BMSN. WE ARE GOLDEN, PLS READ. $$$ BMSN HAS TH
Post# of 5066
Posted On: 05/13/2013 7:45:24 PM
BMSN. WE ARE GOLDEN, PLS READ. $$$
BMSN HAS THE BIG BOYS ON BOARD. BMSN. Green up!!
WE ARE GOLDEN, PLS READ. $$$
BMSN HAS THE BIG BOYS ON BOARD.
Check this out what i found;
"The potential of regenerative medicine products is significant," says Christopher Mizer, the President of Regen BioPharma. "We believe that strategic collaborative relationships between Regen BioPharma, our SAB and Clinartis will facilitate our efforts to create value from that potential by developing proprietary, life sciences technologies and demonstrating their clinical utility."
Regen BioPharma has also entered into a Letter of Intent with Clinartis LLC, a global contract research organization (CRO). Clinartis is a full service global CRO serving pharmaceutical,
biotech and medical device companies to support Phase I - IV drug and device clinical trials in the US and Europe.
More about Dr. Bogin;
Dr. Bogin is the President and CEO of Cromos Pharma, a contract research organization that specializes in Biopharmaceutical clinical outsourcing. He was formerly the Director of Boehringer Ingelheim in charge of the phase IV program for Dabigatran Etexilate.
"Our strong SAB has scientific and regulatory expertise, coupled with Clinartis' access to worldclass researchers and nvestigators will be very instrumental for accelerated commercialization of
the cutting-edge biotechnology research on which Regen BioPharma is focused," according to Bio-Matrix Scientific Group's Chairman & CEO David Koos.
BMSN has now regenerative medicine experts on board and they are:
David White, M.D.,
Wei-Ping Min, M.D.,
Vlad Bogin, M.D.
What a team does BMSN have, look at this;
J. Christopher Mizer has joined the Company as President and Chief Operating Officer of its Regen BioPharma subsidiary. Regen BioPharma is a "superincubator" focused on accelerated development of undervalued intellectual property in the area of stem cells therapies. Mr. Mizer will spearhead license negotiations, development of academic and corporate partnerships, creation of business units, and value optimization of technologies that are being advanced by Regen BioPharma.
David Koos, Chairman & CEO of Bio-Matrix Scientific Group, stated, "We are building a world-class team in the field of translational, regenerative medicine. Mr. Mizer's solid track record of building companies, attracting funding, attaining profitability, and enabling successful exist strategies uniquely positions him to lead the operational aspects of our novel stem cell company."
Mr. Mizer is the founder of Vivaris, Ltd., a private investment partnership focused on life science and healthcare opportunities, and co-founder of ChinaBio Capital Partners. He was formerly an investment banker with Key Capital Markets and a consultant with Ernst and Young. He holds a Master of Science degree in biology and an M.B.A. from Case Western Reserve University.
Seeking for 0,0345 - 0,0712, from this point. After that ,15. Double up!! Long term 1,19. But, if there is a buyout short term, god knows how high it will be. The only thing is, buy some..
BMSN
BMSN HAS THE BIG BOYS ON BOARD. BMSN. Green up!!
WE ARE GOLDEN, PLS READ. $$$
BMSN HAS THE BIG BOYS ON BOARD.
Check this out what i found;
"The potential of regenerative medicine products is significant," says Christopher Mizer, the President of Regen BioPharma. "We believe that strategic collaborative relationships between Regen BioPharma, our SAB and Clinartis will facilitate our efforts to create value from that potential by developing proprietary, life sciences technologies and demonstrating their clinical utility."
Regen BioPharma has also entered into a Letter of Intent with Clinartis LLC, a global contract research organization (CRO). Clinartis is a full service global CRO serving pharmaceutical,
biotech and medical device companies to support Phase I - IV drug and device clinical trials in the US and Europe.
More about Dr. Bogin;
Dr. Bogin is the President and CEO of Cromos Pharma, a contract research organization that specializes in Biopharmaceutical clinical outsourcing. He was formerly the Director of Boehringer Ingelheim in charge of the phase IV program for Dabigatran Etexilate.
"Our strong SAB has scientific and regulatory expertise, coupled with Clinartis' access to worldclass researchers and nvestigators will be very instrumental for accelerated commercialization of
the cutting-edge biotechnology research on which Regen BioPharma is focused," according to Bio-Matrix Scientific Group's Chairman & CEO David Koos.
BMSN has now regenerative medicine experts on board and they are:
David White, M.D.,
Wei-Ping Min, M.D.,
Vlad Bogin, M.D.
What a team does BMSN have, look at this;
J. Christopher Mizer has joined the Company as President and Chief Operating Officer of its Regen BioPharma subsidiary. Regen BioPharma is a "superincubator" focused on accelerated development of undervalued intellectual property in the area of stem cells therapies. Mr. Mizer will spearhead license negotiations, development of academic and corporate partnerships, creation of business units, and value optimization of technologies that are being advanced by Regen BioPharma.
David Koos, Chairman & CEO of Bio-Matrix Scientific Group, stated, "We are building a world-class team in the field of translational, regenerative medicine. Mr. Mizer's solid track record of building companies, attracting funding, attaining profitability, and enabling successful exist strategies uniquely positions him to lead the operational aspects of our novel stem cell company."
Mr. Mizer is the founder of Vivaris, Ltd., a private investment partnership focused on life science and healthcare opportunities, and co-founder of ChinaBio Capital Partners. He was formerly an investment banker with Key Capital Markets and a consultant with Ernst and Young. He holds a Master of Science degree in biology and an M.B.A. from Case Western Reserve University.
Seeking for 0,0345 - 0,0712, from this point. After that ,15. Double up!! Long term 1,19. But, if there is a buyout short term, god knows how high it will be. The only thing is, buy some..
BMSN
(0)
(0)RIVULET MEDIA INC. (RIVU) Stock Research Links
Scroll down for more posts ▼